Abstract
As molecular therapy continues to grow, unanticipated challenges may arise, requiring the institution's therapeutic team to reevaluate its therapeutic protocol to identify and address potential situations and challenges that may occur. This practical pointer will focus on the novel prostate cancer therapy Pluvicto (177Lu-vipivotide tetraxetan) and 2 unique situations and challenges of treating patients at the Theranostic Center at Carilion Clinic, an outpatient facility dedicated to targeted molecular therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have